首页> 外文期刊>Journal of Radiation Research: Official Organ of the Japan Radiation Research Society >Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy
【24h】

Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy

机译:肝内肿瘤和门静脉肿瘤血栓形成的总体反应是接受同步放化疗的肝细胞癌患者的良好预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

This study investigated the prognostic significance of portal vein tumor thrombosis (PVTT) response in hepatocellular carcinoma (HCC) patients treated with localized concurrent chemoradiotherapy (CCRT). We retrospectively analyzed 100 patients treated with CCRT for UICC Stage T2-4N0M0 HCC with PVTT between 2002 and 2011. The radiotherapy (RT) volume included both primary tumor and PVTT, and the median radiation dose was 45 Gy. Treatment response was evaluated for up to 6 months after RT. With respect to PVTT response to treatment, complete response (CR) and partial response (PR) were achieved in 14% and 48% of patients, respectively, yielding an objective response (OR) rate of 62%. PVTT size (≤3cm diameter) was associated with a higher rate of a CR (P = 0.001). The median overall survival (OS) was 11.6 months. Independent prognostic factors for OS were OR of the tumor to RT and a CR of the PVTT. Achieving an OR in both the tumor and the PVTT demonstrated a significant correlation with improved survival (P = 0.002). Progression of intrahepatic metastasis was affected not by CCRT but by the clinical features of the PVTT, particularly the initial PVTT site. PVTT response following CCRT seems prognostically significant. CR of the PVTT was associated with improved survival. Achieving an OR in both the tumor and PVTT was also associated with improved survival.
机译:这项研究调查了门静脉肿瘤血栓形成(PVTT)反应在接受局部同时放化疗(CCRT)治疗的肝细胞癌(HCC)患者中的预后意义。我们回顾性分析了2002年至2011年间100例接受CCRT治疗的UICC T2-4N0M0肝癌合并PVTT的CCRT患者。放疗量包括原发肿瘤和PVTT,中位放射剂量为45 Gy。放疗后长达6个月评估了治疗反应。关于PVTT对治疗的反应,分别有14%和48%的患者达到了完全缓解(CR)和部分缓解(PR),客观缓解(OR)率为62%。 PVTT大小(直径≤3cm)与较高的CR率相关(P = 0.001)。中位总生存期(OS)为11.6个月。 OS的独立预后因素是肿瘤对RT的OR或PVTT的CR。在肿瘤和PVTT中均达到OR值与生存率改善存在显着相关性(P = 0.002)。肝内转移的进展不受CCRT的影响,但受PVTT的临床特征(尤其是初始PVTT部位)的影响。 CCRT后的PVTT反应在预后上似乎很重要。 PVTT的CR与生存率提高相关。在肿瘤和PVTT中达到OR也与存活率提高有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号